Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Drug-eluting Balloons: Experience from Central India
Author(s): Ajinkya Mahorkar , Virag Mahorkar , Uday Mahorkar , et al Added: 1 month ago

Prevention & Chronic Conditions

Intervention
Stent Ablation for Resistant Lesions within and across the Stent Struts
Author(s): Vikas Kadiyala , Khung Keong Yeo Added: 1 year ago

Prevention & Chronic Conditions

MI/ACS
PCI Patient Outcomes With Different DES
Author(s): Jonathan Ong Wei Sheng , Muhammad Bin Idu Jion , Keh Yann Shan , et al Added: 1 month ago

Intervention
ACC 25: Optimizing DAPT Duration
Author(s): Hyo-Soo Kim Added: 1 month ago
ACC 25 - Findings from a stratified study investigating coronary stenting and bleeding risk suggest 3 months are the optimal duration of DAPT after PCI.Dr Hyo-Soo Kim (Seoul National University Hospital, KR) sits down to discuss the first randomized study stratifying patients receiving percutaneous coronary intervention with drug eluting stents according to bleeding risk based on the ARC HBR… View more

Anticoagulation

Intervention
Consequences and Management of Excessive Ostial Stent Protrusion
Author(s): Arditya Damarkusuma Added: 1 year ago
In this video, Dr Arditya Damarkusuma (Universitas Gadjah Mada, ID) presents his case report on aorto-ostial lesions, recently published in ICR Journal.This case covers the restenosis of a markedly protruding stent at the right coronary ostium in a 54-year old man, and is unusual in its 10-year longevity. Intravascular ultrasound-guided in-stent restenosis intervention using a wire bumper… View more

Imaging & Diagnostics

Intervention
ACC 25: The SMART-CHOICE 3 Trial
Author(s): Joo-Yong Hahn Added: 1 month ago
ACC 25 - SMART-CHOICE 3 Trial finds clopidogrel monotherapy to be the optimal anti-thrombotic strategy in high risk patients with contemporary drug-eluting stents.Dr Joo-Yong Hahn (Samsung Medical Center, Seoul, KR) joins us onsite at ACC Conference 2025 to discuss the findings from the SMART-CHOICE 3 study (NCT04418479). The study aims to evaluate the efficacy and safety of clopidogrel… View more

Anticoagulation

Intervention
Job title: Head, Product Development Team, Drug-eluting Stents
TCT 23: AGENT IDE
Author(s): Robert Yeh Added: 1 year ago
TCT 23 - In this short online interview, we are joined by Dr Robert Yeh (Beth Israel Deaconess Medical Center, US) to discuss the findings of the AGENT IDE trial (NCT04647253), sponsored by Boston Scientific. AGENT IDE is a prospective, 2:1 randomized multicenter trial that aimed to compare the AGENT paclitaxel-coated balloon to plain-old balloon angioplasty (POBA) with a commercially available… View more

Intervention
Angela Hoye
Job title: Consultant Cardiologist
Angela Hoye is an Interventional Cardiologist at Castle Hill Hospital, Hull and a Senior Lecturer in Cardiology at the Centre for Cardiovascular and Metabolic Research, Hull York Medical School. She completed cardiology training in East Yorkshire, UK and has a speciality interest in coronary intervention. She worked for two years at the Thoraxcenter, Rotterdam between 2002 and 2004, and… View more
EuroPCR 24: The CAGEFREE II Trial
Author(s): Ling Tao Added: 11 months ago
EuroPCR 2024 — Investigator, Dr Ling Tao joins us to discuss the findings from the CAGEFREE II trial.Compared to drug-eluting stents, drug-coated balloons are associated with faster vessel healing and reduced thrombotic burden, therefore patients treated with DCBs require a less intensive antiplatelet therapy. CAGEFREE II investigated the effectiveness and safety of a tailored one-month DAPT… View more

Intervention